Patents by Inventor Hung-Wei Chih
Hung-Wei Chih has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240071947Abstract: A semiconductor package including a ring structure with one or more indents and a method of forming are provided. The semiconductor package may include a substrate, a first package component bonded to the substrate, wherein the first package component may include a first semiconductor die, a ring structure attached to the substrate, wherein the ring structure may encircle the first package component in a top view, and a lid structure attached to the ring structure. The ring structure may include a first segment, extending along a first edge of the substrate, and a second segment, extending along a second edge of the substrate. The first segment and the second segment may meet at a first corner of the ring structure, and a first indent of the ring structure may be disposed at the first corner of the ring structure.Type: ApplicationFiled: August 30, 2022Publication date: February 29, 2024Inventors: Yu-Ling Tsai, Lai Wei Chih, Meng-Tsan Lee, Hung-Pin Chang, Li-Han Hsu, Chien-Chia Chiu, Cheng-Hung Lin
-
Publication number: 20190010229Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: April 2, 2018Publication date: January 10, 2019Applicant: ImmunoGen, Inc.Inventors: Godfrey AMPHLETT, Wei ZHANG, Michael FLEMING, Hung-Wei CHIH
-
Patent number: 9998720Abstract: An image processing method is provided. The image processing method includes the following steps: blending a plurality of exposure frames captured by one or more image capturing devices using a plurality of exposure times to generate a real-time image; analyzing one or more regions of interest (ROIs) of the real-time image according to ROI information about the one or more ROIs of the real-time image, and accordingly generating an analysis result; and utilizing an image processor for referring to the analysis result to locally adjust image data within the one or more ROIs of the real-time image to generate an adjusted real-time image in real time.Type: GrantFiled: May 11, 2016Date of Patent: June 12, 2018Assignee: MEDIATEK INC.Inventors: Cheng-Che Chan, Hung-Wei Chih, Chung-Yao Hung, Cheng-Che Chen
-
Publication number: 20170332060Abstract: An image processing method is provided. The image processing method includes the following steps: blending a plurality of exposure frames captured by one or more image capturing devices using a plurality of exposure times to generate a real-time image; analyzing one or more regions of interest (ROIs) of the real-time image according to ROI information about the one or more ROIs of the real-time image, and accordingly generating an analysis result; and utilizing an image processor for referring to the analysis result to locally adjust image data within the one or more ROIs of the real-time image to generate an adjusted real-time image in real time.Type: ApplicationFiled: May 11, 2016Publication date: November 16, 2017Inventors: Cheng-Che Chan, Hung-Wei Chih, Chung-Yao Hung, Cheng-Che Chen
-
Publication number: 20170137535Abstract: Pharmaceutical formulations comprising monoclonal anti-Factor D antibodies, and their production and use for the treatment of complement-associated ocular diseases are disclosed. The formulations include pre-lyophilized, lyophilized and reconstituted stable liquid formulations of anti-Factor D antibodies, including lampalizumab.Type: ApplicationFiled: October 27, 2016Publication date: May 18, 2017Inventors: Christopher Petry, Benson Gikanga, Hung-Wei Chih, Jun Liu
-
Publication number: 20160367696Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: May 19, 2016Publication date: December 22, 2016Applicant: ImmunoGen, Inc.Inventors: Godfrey AMPHLETT, Wei ZHANG, Michael FLEMING, Hung-Wei CHIH
-
Patent number: 9114179Abstract: The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention also provides an immunoconjugate formulation that is substantially free of aggregates, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of histidine, sucrose, glycine and sodium chloride, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention further provides an immunoconjugate formulation that is substantially free of both particles and aggregates.Type: GrantFiled: August 3, 2006Date of Patent: August 25, 2015Assignee: ImmunoGen, Inc.Inventors: Wei Zhang, Michael S. Fleming, Godfrey Amphlett, Hung-wei Chih, Elizabeth Bartlett
-
Publication number: 20140294864Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventors: Godfrey AMPHLETT, Wei ZHANG, Michael FLEMING, Hung-Wei CHIH
-
Patent number: 8704848Abstract: A transform model is established by the calibration system for color transformation between a first color space and a second color space. Three first target curves are defined and transformed by the transform model so as to establish three look-up tables. The display is calibrated according to the three look-up tables such that the color temperature of the display may be substantially constant for every gray-level.Type: GrantFiled: June 10, 2009Date of Patent: April 22, 2014Assignee: Young Lighting Technology Inc.Inventors: Chao-Wen Liu, Hung-Wei Chih
-
Publication number: 20110300162Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: August 18, 2011Publication date: December 8, 2011Applicant: IMMUNOGEN, INC.Inventors: Godfrey AMPHLETT, Wei ZHANG, Michael FLEMING, Hung-Wei CHIH
-
Publication number: 20100265266Abstract: A calibration system and a method thereof for color calibration of a display are provided. A transform model is established by the calibration system for color transformation between a first color space and a second color space. Three first target curves are defined and transformed by the transform model so as to establish three look-up tables. The display is calibrated according to the three look-up tables such that the color temperature of the display may be substantially constant for every gray-level.Type: ApplicationFiled: June 10, 2009Publication date: October 21, 2010Applicant: Coretronic Display Solution CorporationInventors: Chao-Wen Liu, Hung-Wei Chih
-
Publication number: 20090142361Abstract: The invention provides a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human the reconstituted composition such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: February 6, 2009Publication date: June 4, 2009Applicant: ImmunoGen, Inc.Inventors: Godfrey AMPHLETT, Wei ZHANG, Michael FLEMING, Hung-Wei Chih
-
Patent number: 7494649Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: GrantFiled: September 14, 2006Date of Patent: February 24, 2009Assignee: ImmunoGen, Inc.Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming, Hung-Wei Chih
-
Publication number: 20070031402Abstract: The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention also provides an immunoconjugate formulation that is substantially free of aggregates, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of histidine, sucrose, glycine and sodium chloride, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention further provides an immunoconjugate formulation that is substantially free of both particles and aggregates.Type: ApplicationFiled: August 3, 2006Publication date: February 8, 2007Inventors: Wei Zhang, Michael Fleming, Godfrey Amphlett, Hung-wei Chih, Elizabeth Bartlett
-
Publication number: 20070009539Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: September 14, 2006Publication date: January 11, 2007Applicant: ImmunoGen, Inc.Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming, Hung-Wei Chih
-
Publication number: 20070009540Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: September 14, 2006Publication date: January 11, 2007Applicant: ImmunoGen, Inc.Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming, Hung-Wei Chih
-
Publication number: 20070009541Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: September 14, 2006Publication date: January 11, 2007Applicant: ImmunoGen, Inc.Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming, Hung-Wei Chih
-
Publication number: 20040241174Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: ApplicationFiled: May 14, 2004Publication date: December 2, 2004Applicant: ImmunoGen, Inc.Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming, Hung-Wei Chih